AmpliPhi Biosciencess C3J Logo

Armata has joined together two seasoned drug development teams, AmpliPhi Biosciences and C3J Therapeutics, to tackle the global and increasingly serious threat of antimicrobial-resistant bacterial infections. Driven by rigorous and innovative science, Armata is developing high-impact, best-in-class bacteriophage therapeutics with the potential to save millions of lives.

Armata Pharmaceuticals
Enter

Synthetic Phage Platform

Transforming Antimicrobial Therapy Through Synthetic Biology

Phages, nature’s natural predators of bacteria, have been in an uninterrupted battle for millions of years — evolving to kill or evade. These powerful natural phages can be purposely engineered to be more efficient killers. The use of synthetic biology tools enables Armata to precisely engineer natural phages in ways that further improve their pharmacological properties and antimicrobial activity, creating supercharged synthetic phages which can be deployed in the clinic as highly effective weapons in the fight against multidrug-resistant bacterial infections. Engineering natural phages broadens their host range, minimizes resistance and improves efficacy through the expression of beneficial moieties such as biofilm-degrading enzymes and antimicrobial peptides (including STAMPs).

Armata is harnessing its proprietary synthetic phage platform to develop targeted therapeutics for the treatment of various multidrug-resistant bacterial infections.
 

Phage Discovery and Phenotyping

Phage Discovery and Phenotyping

Development of synthetic phage products that target a specific pathogen begins with the isolation of powerful natural phages from environmental and clinical samples. Armata’s large library of multidrug-resistant pathogens (e.g. ESKAPE pathogens) and microbiome targets aids in identification of the optimal phage candidates for downstream engineering.

Bioinformatics Powers Engineering

Bioinformatics Powers Engineering

In partnership with Synthetic Genomics, Armata employs next-generation sequencing and a proprietary sequencing database and software for analyses of phages.

Engineering Phage to Confer Desirable Properties

Engineering Phage to Confer Desirable Properties

Depending on the target pathogen, identified natural phages are engineered to enable desirable phenotypes such as wide host range, payload expression, biofilm degradation, resistance prevention, and bioactive peptide display. Engineered phages are evaluated both in vitro and in vivo to determine pharmacological and toxicological parameters to confirm their potential in the clinic.

In-House Formulation Development and CMC Capabilities

Armata has developed and acquired highly skilled process development and phage manufacturing expertise to manage its proprietary platforms with proven capabilities from the bench to clinic. The 40,000+ total sq.ft of research and development facilities are equipped with licensed GMP manufacturing suites enabling phage production, purification and product testing and release.